JPMorgan Upgrades Amicus Therapeutics (FOLD) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- Oil rises over 3% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Janney Upgrades Amicus Therapeutics (FOLD) to Buy
July 1, 2014 6:53 AM EDTJanney Montgomery Scott upgraded Amicus Therapeutics (NASDAQ: FOLD) from Neutral to Buy with a price target of $5.00 (from $2.50).
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $3.34 yesterday.
... MoreAmicus Therapeutics (FOLD) Moves Higher on Volume
June 30, 2014 11:52 AM EDTAmicus Therapeutics (NASDAQ: FOLD) moving to the highs of the session on volume. Shares up 28.7%.
This morning, the company provided... More
Amicus Therapeutics (FOLD) Updates on Migalastat Phase 3; Top-Line Data Expected in Q314
June 30, 2014 7:06 AM EDTAmicus Therapeutics (Nasdaq: FOLD) has provided updates and detailed the statistical analysis plan for its second Phase 3 study (Study 012) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations. The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations.
Study 012 is the first clinical study to compare oral migalastat to standard-of-care enzyme replacement therapies (ERTs)... More
